Yu-Chi Chiu

Yu-Chi Chiu


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
LWLawrence Shih-Hsin Wu
Lawrence Shih-Hsin Wu
YCYu-Chi Chiu
Yu-Chi Chiu
KHKai-Yao Huang
Kai-Yao Huang
TLTzong-Yi Lee
Tzong-Yi Lee
PHPaul Wei-Che Hsu
Paul Wei-Che Hsu
JWJulia Tzu-Ya Weng
Julia Tzu-Ya Weng
Tuberculosis (TB) is the second most common cause of death from infectious diseases. About 90% of those infected are asymptomatic—the so-called latent TB infections (LTBI), with a 10% lifetime chance of progressing to active TB. To further understand the molecular pathogenesis of TB, several molecular studies have attempted to compare the expression profiles between healthy controls and active TB or LTBI patients. However, the results vary due to diverse genetic backgrounds and study designs and the inherent complexity of the disease process. Thus, developing a sensitive and efficient method for the detection of LTBI is both crucial and challenging. For the present study, we performed a systematic analysis of the gene and microRNA profiles of healthy individuals versus those affected with TB or LTBI. Combined with a series of in silico analysis utilizing publicly available microRNA knowledge bases and published literature data, we have uncovered several microRNA-gene interactions that specifically target both the blood and lungs. Some of these molecular interactions are novel and may serve as potential biomarkers of TB and LTBI, facilitating the development for a more sensitive, efficient, and cost-effective diagnostic assay for TB and LTBI for the Taiwanese population.

23 June 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CLChi-Wei Liu
Chi-Wei Liu
CLChou-Jui Lin
Chou-Jui Lin
HHHui-Chun Hu
Hui-Chun Hu
HLHsiu-Jung Liu
Hsiu-Jung Liu
YCYu-Chi Chiu
Yu-Chi Chiu
Lawrence Shih Hsin WuLawrence Shih Hsin Wu
Lawrence Shih Hsin Wu
Pulmonary tuberculosis (TB) caused by Mycobacterium tuberculosis (Mtb) is a global public health concern. Although inflammasome and the toll-like receptor 2 (TLR2) genes play an important role in host defense against Mtb, the associations of polymorphisms in these genes with TB risk are incompletely understood. A total of 230 TB patients and 213 individuals without TB were enrolled in this study. A significant difference in the frequencies of different AIM2 rs2276405 genotypes between the non-TB and TB groups was detected. When the patients were stratified by gender or age, significant differences in genotype frequencies at NLRP3 rs34298354 in men and in non-aged (≤65-year-old) subjects and at IFI16 rs1772408 in women were found. OR analysis showed that the TC rs34298354 genotype in NLRP3 was associated with reduced risk of TB. In women, the AG rs1772408 genotype in IFI16 was associated with decreased TB risk. Haplotype analysis showed that, in comparison with the most common haplotype (T-T) of rs3804099-rs3804100 in the TLR2 gene, the C-T haplotype was associated with an increased risk for TB. Our study indicates that rs34298354 in NLRP3 and rs1772408 in IFI16 protect individuals from TB, and that the less common TLR2 haplotype is associated with increased TB susceptibility.

Verified
Journal Article
Open access
PDF file
CLChing-Yi Lee
Ching-Yi Lee
YCYu-Chi Chiu
Yu-Chi Chiu
YHYi-Chiung Hsu
Yi-Chiung Hsu
The development of tyrosine kinase inhibitors (TKIs) for late-stage epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) represented a drastic change in the treatment of late-stage lung cancer. Drug resistance develops after a certain period of first-line TKI treatment, which has led to decades of changing treatment guidelines for EGFR-mutant NSCLC. This study discussed the potential mechanisms of drug resistance against first-line TKI treatment and potential successive treatment strategies. Next-generation sequencing (NGS) may play a role in the evaluation of drug resistance in first-line TKI treatment. Emerging combination regimens and ongoing trials were discussed. Potential future strategies for treatment and for the management of drug resistance were proposed in this study.

1 January 2020 in Journal of the Formosan Medical Association
Verified
Journal Article
Open access
MLMENG-RUI LEE
MENG-RUI LEE
CLChih-Hsin Lee
Chih-Hsin Lee
Jann-Yuan WangJann-Yuan Wang
Jann-Yuan Wang
YCYu-Chi Chiu
Yu-Chi Chiu
JKJen-Chung Ko
Jen-Chung Ko
LLLi-Na Lee
Li-Na Lee
Background/Purpose: Little remains known regarding whether newer FQ with less antimycobacterial activity (gemifloxacin) would reduce treatment delay. Methods: We identified one hospital-based cohort (HBC) and one population-based cohort (PBC) including patients receiving amoxicillin/clavulanate acid (Beta-lactam), gemifloxacin (Gemi), and fluoroquinolones other than gemifloxacin (Non-Gemi FQ) prior to TB treatment. Results: A total of 201 patients in the HBC and 3544 patients in the PBC were recruited. After 1:1 propensity score matching, TB treatment delay was statistically insignificant between Beta-lactam, Gemi group, and Non-Gemi FQ group in HBC (Beta-lactam vs Gemi: 22.3 +/- 21.4 d vs 28.6 +/- 27.9 d, p = 0.292; Beta-lactam vs Non-Gemi FQ: 33.3 +/- 26.5 d vs 50.3 +/- 47.3 d, p = 0.135) and PBC (Beta-lactam vs Gemi: 26.4 +/- 29.1 vs 25.0 +/- 28.1, p = 0.638; Beta-lactam vs Non-Gemi FQ: 29.4 +/- 36.0 d vs 32.7 +/- 35.0 d, p = 0.124, Non-Gemi FQ vs Gemi: 28.4 +/- 33.0 d vs 25.0 +/- 28.1 d, p = 0.29). Conclusion: While limited by relatively low case number, our study showed that use of gemifloxacin neither results in nor reduces delay in TB treatment. The issue of FQ use on TB treatment delay was also not observed in our study. Early survey and maintaining high clinical alertness remains the key to reducing TB treatment delay. Copyright (C) 2019, Formosan Medical Association. Published by Elsevier Taiwan LLC.

9 May 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CLChi-Wei Liu
Chi-Wei Liu
Lawrence Shih Hsin WuLawrence Shih Hsin Wu
Lawrence Shih Hsin Wu
CLChou-Jui Lin
Chou-Jui Lin
HWHsing-Chu Wu
Hsing-Chu Wu
KLKuei-Chi Liu
Kuei-Chi Liu
YCYu-Chi Chiu
Yu-Chi Chiu
The immune checkpoint proteins were reported to involve to host resistance to Mycobacteria tuberculosis (Mtb). Here, we evaluated 11 single nucleotide polymorphisms (SNPs) in PDCD1, CTLA4, and HAVCR2 genes between participants with and without TB infection. Genomic DNA isolated from 285 patients with TB and 270 controls without TB infection were used to perform the genotyping assay. Odds ratios were used to characterize the association of 11 SNPs with TB risk. In this study, the various genotypes of the 11 SNPs did not differ significantly in frequency between the non-TB and TB groups. When patients were stratified by sex, however, men differed significantly from women in genotype frequencies at HAVCR2 rs13170556. Odds ratios indicated that rs2227982, rs13170556, rs231775, and rs231779 were sex-specifically associated with TB risk. In addition, the combinations of rs2227982/rs13170556 GA/TC in men and the A-C-C haplotype of rs231775-rs231777-rs231779 in women were significantly associated with TB risk. Our results indicate that rs2227982 in PDCD1 and rs13170556 in HAVCR2 are associated with increased TB susceptibility in men and that the CTLA4 haplotype appears protective against TB in women.

2 November 2020 in Analytical Cellular Pathology
Verified
Journal Article
Open access
PDF file
CWChiao-En Wu
Chiao-En Wu
CCChing-Fu Chang
Ching-Fu Chang
LKLiao Kou-Sheng
Liao Kou-Sheng
JCJu Chiang
Ju Chiang
YCYu-Chi Chiu
Yu-Chi Chiu
YCYu-Chi Chiu
Yu-Chi Chiu
Background. PD-L1 expression is an important predictive factor of response to therapy with immune checkpoint inhibitors (ICIs). This study was designed to retrospectively analyze the concordance of PD-L1 measurements using three different assays (Dako22C3, Dako28-8, and SP142) in NSCLC patients and to find possible predictors of high PD-L1 expression. Materials and Methods. Data of 144 patients with histologically confirmed NSCLC and available PD-L1 measurements treated at the Taoyuan General Hospital from 2018 to 2019 were retrospectively reviewed in the study. Patients characteristics, including age, sex, clinical stage (T, N, and M) of NSCLC (AJCC, 8th edition), and EGFR/ALK alterations, were analyzed for association with PD-L1 expression. Results. Measurements of PD-L1 expression levels with Dako22C3 and Dako28-8 were comparable while SP142 showed lower levels of PD-L1 expression. The overall agreement between Dako22C3 and Dako28-8 was 82.2 and 91.6 for both 1 and 50 TPS cut-offs, respectively. The above findings were confirmed by Cohens kappa. In addition, we found that PD-L1 expression was significantly associated with advanced N stage but not with T and M stages. Conclusion. Dako22C3 and Dako28-8 showed comparable results in assessing PD-L1 levels. Future prospective studies are needed to validate these findings. N stage may be a good predictor for PD-L1 expression.